HUMA Humacyte Inc
Company Analysis
Latest News
🟢 Humacyte is trading 5% up today after V012 Phase 3 ATEV met primary endpoint
Humacyte is trading 5.06% up at $0.43 on October 23, 2026, after positive interim V012 Phase 3 results presented at ASN Kidney Week. - In the first 80...
🔴 Humacyte is trading 6.15% down — catalyst remains unclear
Humacyte is trading at $0.40, down 6.15%, with the catalyst unclear. - No clear company-specific announcement explaining the October 19 decline surfaced in the...
🟢 Humacyte is trading 6% up in pre-market
Humacyte is trading at $0.46, up 6.06% in pre-market, with the catalyst uncertain. - The October 16 close was $0.43. - Humacyte’s October 15 release reported...
🟢 Humacyte is trading 6.83% up in after-hours trading; catalyst remains uncertain
Humacyte is trading at $0.46, up 6.83%, with no clearly verified company-specific announcement explaining the after-hours move. - Humacyte’s October 15 update...
Humacyte's Lab-Grown Blood Vessel Wins Over 44% More Hospitals, but Can a $0.40 Stock Survive Long Enough to Capitalize?
Shares of Humacyte surged 12.1% to $0.40 after the company reported that hospitals ordering its lab-grown human blood vessel jumped 44% in a single quarter — a...
🟢 Humacyte is trading 12.06% up today as hospitals ordering Symvess rose 44%
Humacyte is trading 12.06% up at $0.40 after its October 15 commercial update reported a 44% increase in hospitals ordering Symvess. - Ordering hospitals rose...
🟢 Humacyte is trading 5.8% up in after-hours trading
Humacyte is trading 5.82% up at $0.37 after the October 14 regular-session close of $0.35; no clear company-specific after-hours catalyst was identified. -...
🟢 Humacyte is trading 5.3% up; no clear catalyst identified
Humacyte is trading 5.27% up at $0.38 on October 14, 2026, with no clear company-specific catalyst identified. - The Phase 3 V012 presentation announcement...
🟢 Humacyte is trading 5.88% up in pre-market on October 14, 2026 with no clear catalyst
Humacyte is trading at $0.38, up 5.88% in pre-market, with no clear company-specific catalyst identified. - Pre-market volume was not provided. - Humacyte...
🔴 Humacyte is trading 6.3% down with no clear catalyst
Humacyte is trading 6.3% lower at $0.37 on October 13, 2026; no specific catalyst for the decline has been identified. - Major U.S. indices are nearly flat,...
🔴 Humacyte is trading 11% down with no clear catalyst identified
Humacyte is trading 10.51% down at $0.40, with no clear company-specific announcement identified for the October 9 move. - The decline extends a 5.34% drop on...
🔴 Humacyte is trading 6% down as recent decline continues
Humacyte is trading at $0.42 (-6.13%), with no identified company-specific catalyst for the October 9 decline. - Shares also fell 5.34% on October 8,...
🟢 Humacyte is trading 10% up in pre-market; rebound catalyst remains unclear
Humacyte is trading at $0.49, up 9.84%, in pre-market on October 9, 2026; no fresh company-specific announcement explaining the move was identified. - The...
🔴 Humacyte is trading 5.55% down on October 8, 2026 amid biotech-sector weakness; direct cause remains unclear
Humacyte is trading at $0.45, down 5.55% on October 8; no clear company-specific announcement explaining the decline was identified. - Barclays maintained a...
🟢 Humacyte is trading 5.8% up in pre-market
Humacyte is trading 5.8% up at $0.51 in pre-market on October 7, 2026, versus its October 6 close of $0.48; no clear company-specific announcement explaining...
🔴 Humacyte is trading 6% down with no clear catalyst identified
Humacyte is trading at $0.49, down 6.02%, with no clear company-specific catalyst identified for the October 5 decline. - Humacyte’s latest listed press...
🟢 Humacyte is trading 5.6% up today amid a broad market rally
Humacyte is trading at $0.53, up 5.61%, alongside a broad market rally. - The S&P 500, Nasdaq and Dow were all higher, with the Nasdaq gaining the most. -...
Humacyte Investor State Street Sells 2.2 Million Shares, Cuts Stake 72.3%
State Street Corp. sold 2,201,392 shares of Humacyte, Inc., reducing its stake by 72.3%. It now owns 842,537 shares, or 0.30% of the company, valued at...
🟢 Humacyte is trading 6.8% up in pre-market — no clear company-specific catalyst identified
Humacyte is trading 6.8% up at $0.59 before the September 28, 2026 session; no clear company-specific catalyst was identified. - The latest notable company...
🟢 Humacyte is trading 5.49% up today in pre-market with no clear catalyst
Humacyte is trading at $0.60, up 5.49%, with no clear company-specific catalyst identified for September 25, 2026. • Recent company releases concern an...